Recently published articles about Difficult to Treat Depression
Narrative Review
Immune Targeted Therapies for Depression: Antidepressant Effects of Monoclonal Antibodies
June 24, 2024
Immune dysregulation may contribute to treatment resistance in depression. Monoclonal antibodies have shown promise in treating depression when used for inflammatory disorders and may offer new hope for patients...
Recent JCP Articles on Difficult to Treat Depression
Cross Talk: Case Conferences From MGH
Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression
April 5, 2023
A 61-year-old patient with TRD and a history of self-criticism sought ketamine assisted psychotherapy. Experts from diverse therapeutic perspectives discuss this intriguing case.
Recent PCC Articles on Difficult to Treat Depression
Narrative Review
L-Methylfolate as Adjunctive Therapy in MDD Treatment
May 9, 2023
l-Methylfolate is effective as an adjunctive treatment in MDD and may especially benefit patients with higher body mass index and inflammation.
l-Methylfolate as Adjunctive Therapy in the Treatment of Major Depressive Disorder">
Featured Difficult to Treat Depression Research
Original Research
Ketamine vs Esketamine for TRD
February 1, 2023
Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
Systematic Review
Predictors and Risk Factors of Treatment-Resistant Depression
November 13, 2023
Early identification of individuals with major depressive disorder who are likely to develop treatment-resistant depression (TRD) is needed. This study reviewed the literature to identify and categorize the predictors...
